Neuraxis, Inc. Issues Preliminary Q1 2026 Cash Update

Neuraxis, Inc. (NYSE American: NRXS), a healthcare company headquartered in Carmel, Indiana, has released a Form 8-K current report with a key preliminary financial update for investors and shareholders.

Key Points of the Report

• Preliminary Cash Position: As of March 31, 2026, Neuraxis, Inc. expects its cash and cash equivalents to be approximately \$7.1 million on a preliminary and unaudited basis.
• Nature of the Estimate: This cash estimate was prepared by Neuraxis management and has NOT been audited, reviewed, or subject to any procedures by the company’s independent registered public accounting firm. The estimate could change, and any changes could be material.
• Upcoming Financials: The company intends to complete and release its full financial statements for the three months ended March 31, 2026, subsequent to this preliminary 8-K filing.

Important Details for Shareholders

• Shareholder Caution: The company has specifically warned that “undue reliance should not be placed on these preliminary estimates.” The final audited results may materially differ from the preliminary figures.
• Potential Price Sensitivity: The disclosure of the company’s cash position is material information that may impact the valuation and trading of Neuraxis shares, especially considering the company’s status as an emerging growth company and the importance of liquidity in the current market environment.
• Regulatory Context: The information disclosed in Item 2.02 of this 8-K is NOT incorporated by reference into any registration statement or other filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless specifically referenced elsewhere.

Other Notable Information

• Securities Registered: Neuraxis’ common stock (par value \$0.001) is listed on the NYSE American under the trading symbol NRXS.
• Emerging Growth Company: Neuraxis is classified as an emerging growth company, which can have implications for its financial reporting obligations and the adoption of new accounting standards.
• No Other Disclosures: The company checked “N/A” for any former name or address changes and did not indicate any written communications, proxy soliciting materials, or pre-commencement tender offers in this filing.

Potential Share Price Impact

The preliminary disclosure of a \$7.1 million cash position could influence investor perception of Neuraxis’ liquidity and financial health. However, investors should be aware that this figure is subject to change and has not been audited. The final, audited results—when released—may further impact the stock price depending on whether they confirm, exceed, or fall short of this estimate.

Company Details

• Address: 11611 N. Meridian St, Suite 330, Carmel, IN 46032
• Phone: (812) 689-0791

Disclaimer: This article is based on preliminary and unaudited information disclosed by Neuraxis, Inc. in its Form 8-K filed on April 21, 2026. The information presented herein may be subject to change following the release of the company’s official, audited financial statements. Investors should not rely solely on these preliminary figures when making investment decisions and are urged to await the full quarterly financial results. This article does not constitute investment advice.

View Neuraxis, INC Historical chart here